

Sathish K R Padi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5041567/publications.pdf>

Version: 2024-02-01

22
papers

663
citations

840776

11
h-index

1199594

12
g-index

23
all docs

23
docs citations

23
times ranked

1278
citing authors

#	ARTICLE	IF	CITATIONS
1	Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. <i>Cell Death and Disease</i> , 2010, 1, e105-e105.	6.3	185
2	MicroRNA-627 Mediates the Epigenetic Mechanisms of Vitamin D to Suppress Proliferation of Human Colorectal Cancer Cells and Growth of Xenograft Tumors in Mice. <i>Gastroenterology</i> , 2013, 145, 437-446.	1.3	115
3	MMP-9 Responsive PEG Cleavable Nanovesicles for Efficient Delivery of Chemotherapeutics to Pancreatic Cancer. <i>Molecular Pharmaceutics</i> , 2014, 11, 2390-2399.	4.6	91
4	Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. <i>Cell Death and Disease</i> , 2014, 5, e1486-e1486.	6.3	72
5	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 7349.	12.8	51
6	Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2710-2721.	4.1	38
7	Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. <i>Oncotarget</i> , 2017, 8, 30199-30216.	1.8	32
8	Insulin receptor substrate 1 is a substrate of the Pim protein kinases. <i>Oncotarget</i> , 2016, 7, 20152-20165.	1.8	22
9	PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. <i>Molecular Oncology</i> , 2020, 14, 974-990.	4.6	18
10	EDC3 phosphorylation regulates growth and invasion through controlling P-body formation and dynamics. <i>EMBO Reports</i> , 2021, 22, e50835.	4.5	17
11	Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20505-20510.	7.1	16
12	PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1809-1821.	4.1	6
13	Key for successful T-ALL treatment. <i>Blood</i> , 2021, 137, 2422-2423.	1.4	0
14	Abstract 2296: Regulation of P-body dynamics and formation in tumors through EDC3 phosphorylation by PIM and AKT. , 2021, , .		0
15	Abstract 4739: miR-627 and histone demethylase JMJD1A as new therapeutic targets in colon cancer. , 2012, , .		0
16	Therapeutic Targeting of PIM Protein Kinases in a Subset of T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2742-2742.	1.4	0
17	Abstract 5820: Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. , 2017, , .		0
18	Abstract 3017: Role of long noncoding RNA H19 in driving enzalutamide resistant neuroendocrine prostate cancer. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	Abstract PR01: Phosphorylation of DEPDC5 by the Pim-1 protein kinase, a cancer driver, stimulates mTORC1 activity by regulating the DEPDC5- Rag GTPase interaction. , 2020, ,		0
20	ROS Induced by Chemo- and Targeted Therapy Promote Apoptosis in Cancer Cells. , 2022, , 583-598.		0
21	Oxidative Stress in Cancer: Therapeutic Implications of Small-Molecule Kinase Inhibitors. , 2022, , 1-17.		0
22	Synthesis of 2-oxoquinoline derivatives as dual pim and mTORC protein kinase inhibitors. Medicinal Chemistry Research, 0, ,	2.4	0